Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05645380 | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC(NeoTRACT) | active not recruiting | Phase 2 | 139 | University of Kansas Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02734290 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 29 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 |
| NCT04373031 | Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 12 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03756298 | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 2 | 284 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06062810 | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04837820 | The Effect of Acupuncture on Cancer-Related Cognitive Difficulties | active not recruiting | Phase 2 | 270 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03366844 | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | active not recruiting | Phase 1 / Phase 2 | 66 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03820141 | Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer(DTP) | active not recruiting | Phase 2 | 51 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02326974 | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | active not recruiting | Phase 2 | 164 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02917421 | Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations(ART) | active not recruiting | Phase 1 / Phase 2 | 88 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03377387 | Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02754752 | Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment | active not recruiting | Phase 2 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06840483 | Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | active not recruiting | Phase 2 | 66 | BicycleTx LimitedINDUSTRY | 7 | Apr 15, 2026 | clinicaltrials |
| NCT04920708 | Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression(FAIM) | active not recruiting | Phase 2 | 57 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03650894 | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | active not recruiting | Phase 2 | 30 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06702618 | Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer | active not recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03315364 | Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy(OPTIMAL) | active not recruiting | Phase 2 / Phase 3 | 549 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 5 | Apr 1, 2026 | clinicaltrials |
| NCT02890082 | Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer(PRESAGE) | active not recruiting | Phase 2 | 102 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02482376 | Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer | active not recruiting | Phase 2 | 110 | Duke UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05227664 | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 120 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04293393 | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients(CARABELA) | active not recruiting | Phase 2 | 200 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02712723 | Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer(FELINE) | active not recruiting | Phase 2 | 121 | Qamar KhanOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04454528 | BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy(BreastVAX) | active not recruiting | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05810870 | PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin(SABINA) | active not recruiting | Phase 2 | 14 | MedSIROTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04829604 | ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | active not recruiting | Phase 2 | 72 | Ambrx, Inc.INDUSTRY | 3 | Mar 9, 2026 | clinicaltrials |
| NCT05573555 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | active not recruiting | Phase 1 / Phase 2 | 20 | PfizerINDUSTRY | 4 | Mar 9, 2026 | clinicaltrials |
| NCT03384914 | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 119 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00616967 | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | active not recruiting | Phase 2 | 68 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03386617 | AKY15-HK-301_NEPA Study | active not recruiting | Phase 2 | 55 | Chinese University of Hong KongOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03272334 | Her2-BATS and Pembrolizumab in Metastatic Breast Cancer(Breast-47) | active not recruiting | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07421141 | De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer(Opti-HER2) | active not recruiting | Phase 2 | 186 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02778685 | Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer | active not recruiting | Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04176848 | CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | active not recruiting | Phase 2 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05892068 | A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02624973 | PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial(PETREMAC) | active not recruiting | Phase 2 | 200 | Haukeland University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05383196 | Onvansertib + Paclitaxel In TNBC | active not recruiting | Phase 1 / Phase 2 | 50 | Antonio Giordano, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT02747004 | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer(Next MONARCH 1) | active not recruiting | Phase 2 | 234 | Eli Lilly and CompanyINDUSTRY | 14 | Feb 6, 2026 | clinicaltrials |
| NCT06175390 | Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer(SKYLINE) | active not recruiting | Phase 2 | 81 | Institut CurieOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03808662 | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | active not recruiting | Phase 2 | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04454437 | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments | active not recruiting | Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT01984138 | REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy(REVIVE) | active not recruiting | Phase 2 | 33 | Polly A. Niravath, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05968144 | Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness(ADRIAN) | active not recruiting | Phase 1 / Phase 2 | 30 | University of Maryland, BaltimoreOTHER | 1 | Jan 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2026source: clinicaltrials